US clears fifths indication for Roche eye drug
Roche group Genentech’s application to use Lucentis for the treatment of myopic choroidal neovascularization (mCNV) has been approved by the US Food and Drug Administration, giving patients the chance to access the first anti-vascular endothelial growth factor (VEGF) therapy for the condition.
Read More
